Patents by Inventor Mark Andrew Youngman

Mark Andrew Youngman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemical compounds as H—PGDS inhibitors
    Patent number: 11149035
    Abstract: A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: October 19, 2021
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED
    Inventors: David Norman Deaton, Barry George Shearer, Mark Andrew Youngman
  • Chemical Compounds as H-PGDS Inhibitors
    Publication number: 20200123152
    Abstract: A compound of formula (I) wherein R1, R2, R3, R4, X, Y, and A are as defined herein. The compounds of the present invention are inhibitors of hematopoletic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: June 11, 2018
    Publication date: April 23, 2020
    Inventors: David Norman DEATON, Barry George SHEARER, Mark Andrew YOUNGMAN
  • Cyclic sulfonamides as sodium channel blockers
    Patent number: 9714252
    Abstract: The present disclosure provides cyclic sulfonamides of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, and n are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. For example, compounds of the present disclosure are useful for treating pain.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 25, 2017
    Assignee: Purdue Pharma L.P.
    Inventor: Mark Andrew Youngman
  • Cyclic Sulfonamides as Sodium Channel Blockers
    Publication number: 20150336974
    Abstract: The present disclosure provides cyclic sulfonamides of Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, and n are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. For example, compounds of the present disclosure are useful for treating pain.
    Type: Application
    Filed: December 18, 2013
    Publication date: November 26, 2015
    Inventor: Mark Andrew Youngman